ESOPJun 4, 2026, 04:13 PM
Myriad Genetics Stockholders Approve Equity Plans for 12.4M Shares
AI Summary
Myriad Genetics, Inc. stockholders approved an amendment to the 2012 Employee Stock Purchase Plan, increasing authorized shares by an additional 4,000,000. Stockholders also approved the 2026 Employee, Director and Consultant Equity Incentive Plan, which authorizes 8,463,567 shares, including shares rolled over from the 2017 Plan. Additionally, three Class III directors were elected, Ernst & Young LLP was ratified as the independent auditor, and the advisory vote on named executive officer compensation was approved.
Key Highlights
- Stockholders approved an amendment to the 2012 Employee Stock Purchase Plan, adding 4,000,000 shares.
- The 2026 Employee, Director and Consultant Equity Incentive Plan was approved.
- The 2026 Plan authorizes 8,463,567 shares, including 2,063,567 rolled over from the 2017 Plan.
- Paul M. Bisaro, Rashmi Kumar, and Lee N. Newcomer, M.D. were elected as Class III directors.
- Ernst & Young LLP was ratified as the independent auditor for 2026.
- The advisory vote on named executive officer compensation was approved.
- A quorum of 77,758,631 shares, or 82.33% of outstanding shares, was present at the Annual Meeting.
Price Impact
More from MYGN